Sorafenib is an orally administered active multikinase inhibitor for metastatic renal cell carcinoma that is now considered a standard agent.
Skin toxicity, such as hand-foot skin reaction, is one of the frequent adverse effects of sorafenib. On the other hand, sorafenib-induced erythema multiforme is very rare, and Stevens-Johnson syndrome and toxic epidermal necrolysis induced by sorafenib have not been reported. We report the first case of Stevens-Johnson syndrome caused by sorafenib for metastatic renal cell carcinoma.
Written by:
Ikeda M, Fujita T, Amoh Y, Mii S, Matsumoto K, Iwamura M. Are you the author?
Department of Urology, Kitasato University School of Medicine, Sagamihara, Japan.
Reference: Urol Int. 2013 Aug 16. Epub ahead of print.
doi: 10.1159/000351918
PubMed Abstract
PMID: 23969404
UroToday.com Renal Cancer Section
